Mostrar el registro sencillo del ítem

dc.contributor.authorFerreiro Iglesias, Aida
dc.contributor.authorMontes, A.
dc.contributor.authorPérez Pampín, Eva 
dc.contributor.authorCañete, J. D.
dc.contributor.authorRaya, E.
dc.contributor.authorMagro-Checa, C.
dc.contributor.authorVasilopoulos, Y.
dc.contributor.authorCaliz, R.
dc.contributor.authorFerrer, M. A.
dc.contributor.authorJoven, B.
dc.contributor.authorCarreira, P.
dc.contributor.authorBalsa, A.
dc.contributor.authorPascual-Salcedo, D.
dc.contributor.authorBLANCO GARCIA, FRANCISCO JAVIER 
dc.contributor.authorMoreno-Ramos, M. J.
dc.contributor.authorManrique-Arija, S.
dc.contributor.authorOrdoñez, M. D. C.
dc.contributor.authorAlegre-Sancho, J. J.
dc.contributor.authorNarvaez, J.
dc.contributor.authorNavarro-Sarabia, F.
dc.contributor.authorMoreira, V.
dc.contributor.authorValor, L.
dc.contributor.authorGarcia-Portales, R.
dc.contributor.authorMarquez, A.
dc.contributor.authorGómez-Reino Carnota, Juan Jesús 
dc.contributor.authorMartin, J.
dc.contributor.authorGonzález Martínez-Pedrayo, Antonio 
dc.date.accessioned2021-10-04T09:40:25Z
dc.date.available2021-10-04T09:40:25Z
dc.date.issued2019
dc.identifier.issn1932-6203
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/30818333es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/15438
dc.description.abstractResearch in rheumatoid arthritis (RA) is increasingly focused on the discovery of biomarkers that could enable personalized treatments. The genetic biomarkers associated with the response to TNF inhibitors (TNFi) are among the most studied. They include 12 SNPs exhibiting promising results in the three largest genome-wide association studies (GWAS). However, they still require further validation. With this aim, we assessed their association with response to TNFi in a replication study, and a meta-analysis summarizing all non-redundant data. The replication involved 755 patients with RA that were treated for the first time with a biologic drug, which was either infliximab (n = 397), etanercept (n = 155) or adalimumab (n = 203). Their DNA samples were successfully genotyped with a single-base extension multiplex method. Lamentably, none of the 12 SNPs was associated with response to the TNFi in the replication study (p > 0.05). However, a drug-stratified exploratory analysis revealed a significant association of the NUBPL rs2378945 SNP with a poor response to etanercept (B = -0.50, 95% CI = -0.82, -0.17, p = 0.003). In addition, the meta-analysis reinforced the previous association of three SNPs: rs2378945, rs12142623, and rs4651370. In contrast, five of the remaining SNPs were less associated than before, and the other four SNPs were no longer associated with the response to treatment. In summary, our results highlight the complexity of the pharmacogenetics of TNFi in RA showing that it could involve a drug-specific component and clarifying the status of the 12 GWAS-drawn SNPs.en
dc.language.isoeng
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.meshAdult*
dc.subject.meshGenetic Markers*
dc.subject.meshMiddle Aged*
dc.subject.meshHumans*
dc.subject.meshYoung Adult*
dc.subject.meshGenome-Wide Association Study*
dc.subject.meshArthritis*
dc.subject.meshAged*
dc.titleEvaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanerceptes
dc.typeArtigoes
dc.authorsophosFerreiro-Iglesias, A.
dc.authorsophosMontes, A.
dc.authorsophosPerez-Pampin, E.
dc.authorsophosCañete, J. D.
dc.authorsophosRaya, E.
dc.authorsophosMagro-Checa, C.
dc.authorsophosVasilopoulos, Y.
dc.authorsophosCaliz, R.
dc.authorsophosFerrer, M. A.
dc.authorsophosJoven, B.
dc.authorsophosCarreira, P.
dc.authorsophosBalsa, A.
dc.authorsophosPascual-Salcedo, D.
dc.authorsophosBlanco, F. J.
dc.authorsophosMoreno-Ramos, M. J.
dc.authorsophosManrique-Arija, S.
dc.authorsophosOrdoñez, M. D. C.
dc.authorsophosAlegre-Sancho, J. J.
dc.authorsophosNarvaez, J.
dc.authorsophosNavarro-Sarabia, F.
dc.authorsophosMoreira, V.
dc.authorsophosValor, L.
dc.authorsophosGarcia-Portales, R.
dc.authorsophosMarquez, A.
dc.authorsophosGomez-Reino, J. J.
dc.authorsophosMartin, J.
dc.authorsophosGonzalez, A.
dc.identifier.doi10.1371/journal.pone.0213073
dc.identifier.pmid30818333
dc.identifier.sophos30736
dc.issue.number2es
dc.journal.titlePLoS Onees
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario de A Coruña::Reumatoloxía
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Reumatoloxía
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Biomédica da Coruña (INIBIC)
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)
dc.page.initiale0213073es
dc.relation.publisherversionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395028/pdf/pone.0213073.pdf
dc.rights.accessRightsopenAccess
dc.subject.decsanciano*
dc.subject.decsmarcadores genéticos*
dc.subject.decsadulto joven*
dc.subject.decsmediana edad*
dc.subject.decshumanos*
dc.subject.decsestudio de asociación genómica completa*
dc.subject.decsadulto*
dc.subject.decsartritis*
dc.subject.keywordCHUAC
dc.subject.keywordCHUS
dc.subject.keywordINIBIC
dc.subject.keywordIDIS
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)
dc.typesophosArtículo Original
dc.volume.number14es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional